Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.09 USD | -1.70% | -3.00% | +14.52% |
May. 09 | X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise | MT |
May. 09 | Verona Pharma Signs Financing Agreements for Up to $650 Million | MT |
Financials (USD)
Sales 2024 * | 509M | Sales 2025 * | 553M | Capitalization | 3.19B |
---|---|---|---|---|---|
Net income 2024 * | 341M | Net income 2025 * | 345M | EV / Sales 2024 * | 6.26 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.77 x |
P/E ratio 2024 * |
9.42
x | P/E ratio 2025 * |
9.82
x | Employees | - |
Yield 2024 * |
8.04% | Yield 2025 * |
8.31% | Free-Float | 98.08% |
Latest transcript on Hercules Capital, Inc.
1 day | -1.70% | ||
1 week | -3.00% | ||
Current month | -0.16% | ||
1 month | +5.06% | ||
3 months | +9.40% | ||
6 months | +19.01% | ||
Current year | +14.52% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Bluestein
CEO | Chief Executive Officer | 45 | 10-11-16 |
Seth H. Meyer
DFI | Director of Finance/CFO | 55 | 19-03-03 |
Kiersten Botelho
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gayle Crowell
BRD | Director/Board Member | 73 | 19-02-03 |
Robert Badavas
CHM | Chairman | 71 | 06-02-28 |
Director/Board Member | 61 | 23-09-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 19.09 | -4.07% | 1,635,336 |
24-05-10 | 19.9 | +0.20% | 1,540,640 |
24-05-09 | 19.86 | +0.81% | 1,237,564 |
24-05-08 | 19.7 | -0.30% | 1,040,594 |
24-05-07 | 19.76 | +0.41% | 966,000 |
Delayed Quote Nyse, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.52% | 3.19B | |
+31.41% | 2.06B | |
+9.31% | 1.51B | |
-11.54% | 1.19B | |
+10.41% | 720M | |
+8.49% | 652M | |
+26.90% | 553M | |
-4.17% | 497M | |
+24.84% | 469M | |
+3.90% | 306M |
- Stock Market
- Equities
- HTGC Stock